FDA report doubts need for Advair approval at higher doses

04/28/2007 | MarketWatch · Wall Street Journal, The

An FDA report in advance of a Tuesday advisory committee meeting casts doubt on whether higher doses of Advair should be approved to treat patients with chronic obstructive pulmonary disease to increase survival and reduce exacerbations. GlaxoSmithKline's Advair already is approved as an asthma treatment and to treat COPD patients at 250/50 microgram doses, but GSK wants clearance at 500/50 microgram doses.

View Full Article in:

MarketWatch · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ